But Verona is off to a strong start as Ohtuvayre generated sales of $42 million in 2024, the company reported on Tuesday.

Opens in a new tab or window There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease ...

In a cohort of adults with chronic obstructive pulmonary disease (COPD), receiving fluticasone-umeclidinium-vilanterol was ...

Breztri is a medication used to treat COPD ... to eco-friendly inhaler propellant " was originally created and published by ...

Qualcomm and its rival Propeller are emerging as the tech companies to partner with in the development of smart inhalers. Virtually all the companies active in the asthma and COPD markets have ...

Budesonide-glycopyrrolate-formoterol does not improve clinical outcomes compared with fluticasone-umeclidinium-vilanterol ...

A study compares budesonide-glycopyrrolate-formoterol and fluticasone-umeclidinium-vilanterol, revealing insights on COPD ...

Purpose. Special considerations in the selection of medication inhaler devices for elderly patients with chronic obstructive pulmonary disease (COPD) in the ambulatory care setting are reviewed.

Jennifer Trevor, M.D., associate professor in the UAB Division of Pulmonary, Allergy, and Critical Care Medicine ... to-severe asthma to use a patient-activated, reliever-triggered inhaled ...

Inhalers may be prescribed to people who have a variety of health conditions both chronic and acute, including asthma, chronic obstructive pulmonary disease (COPD), and bronchitis. If you're new ...

More information: William B Feldman et al, Comparative effectiveness and safety of single inhaler triple therapies for chronic obstructive pulmonary disease: new user cohort study, BMJ (2024).